secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001628280-25-010775
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Q4 revenue $15.1M, positive adjusted EBITDA; FY revenue $37.2M, no debt
-------------------------------------------------------------------------------

- Q4 total revenue $15.1M ($13.7M HEPZATO US, $1.4M CHEMOSAT Europe); FY total $37.2M.
- Q4 net loss narrowed to $3.4M from $11.1M; FY net loss $26.4M from $47.7M.
- Q4 non-GAAP adjusted EBITDA positive $4.6M; FY adjusted EBITDA loss $2.5M.
- Year-end cash & investments $53.2M; no debt; warrant exercises generated $41.3M in 2024.
- 16 active US centers; FDA clearance for Phase 2 HEPZATO trial in mCRC; NCCN update recommends HEPZATO for mUM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828025010775/0001628280-25-010775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828025010775/dcth-20250306.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-010775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer